• Limei Zhang, Mario A Zetter, Enrique C Guerra, Vito S Hernández, Sushil K Mahata, and Lee E Eiden.
• Dept. Physiology, Laboratory of Systems Neuroscience, School of Medicine, National Autonomous University of Mexico, Mexico City, Mexico.
• J. Neuroendocrinol. 2021 Feb 1; 33 (2): e12935.

AbstractCoronavirus disease 2019 (COVID-19) has become the most critical pandemic of the 21st Century and the most severe since the 1918 influenza pandemic. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infects the host by binding to angiotensin-converting enzyme 2 (ACE2). The role of ACE2 in the pathophysiology of coronavirus disease 2019 (COVID-19) is a topic of debate, with clinical and experimental evidence indicating a multifaceted relationship between ACE2 activity and disease severity. Here, we review the mechanisms by which the peptidergic substrates and products of ACE and ACE2 contribute to physiological and pathophysiological processes and hypothesise how down-regulation of ACE2 by SARS-CoV-2 cellular entry disrupts homeostasis. A better understanding of the endocrinology of the disease, in particular the neuroendocrinology of ACE2 during COVID-19, may contribute to the timely design of new therapeutic strategies, including the regulation of ACE2 itself by steroid hormones, to ameliorate the severity of COVID-19.© 2021 British Society for Neuroendocrinology.

16 keywords...

hide…